Canakinumab, a new breakthrough drug that reduces heart attacks and cancer in clinical trials
Canakinumab, an anti-inflammatory drug, reduced cancer and heart attacks by 25% in the CANTOS study of last year.
Part of the Best of 2017 lookback
Canakinumab, according to authors of a recent CANTOS study, reduced cancer and heart attacks by 50%. This was achieved by reducing chronic inflammation. This report was first published on LongevityFacts in August 2017 and has since been updated. Brady Hartman is the author.
Researchers announced in late August that they have discovered a drug which can reduce the risk of heart attacks by a quarter while reducing cancer risk by half. Researchers announced that this new medicine could prevent tens and thousands of deaths due to heart attacks and cancer.
The biggest breakthrough since Statins
Harvard researchers believe the discovery will \”usher in a new age\” of medical treatment. Doctors hailed the new drug, which they presented at a large gathering of heart experts as \”the biggest breakthrough since statins.\”
Source:
New Breakthrough Drug Canakinumab Slashes Heart Attack and Cancer in Clinical Trial
